Retrospective Analysis of Intravaginal Brachytherapy in Adjuvant Treatment of Early Endometrial Cancer

Table 2

3-, 5-, and 10-OS, DFS, and LRFS in treated and observed groups and among patients with low and medium risk of recurrence.

Groups and subgroups
	3-OS	5-OS	10-OS
Treated	96,86%,	93%,	81,8%	NS
versus
Observed	100%	95,12%	93,3%
Treated
Low risk	100%	100%	93,75%,	SS
versus
Medium risk	94,34%,	87,55%	72,01%
Observed
Low risk	100%	100%	96,15%,	NS
versus
Medium risk	100%	90,95%	90,95%
	3 - DFS	5 -DFS	10 - DFS
Treated	96,74%,	95,58%,	95,58%,	NS
versus
Observed	97,14%,	93,98%	89,7%.
Treated
Low risk	100%	97,5%	97,5%	NS
versus
Medium risk	93,91%,	93,91%,	93,91%,
Observed
Low risk	93,75%	93,75%	84,38%,	NS
versus
Medium risk	100%	94,02%,	94,02%,
	3 - LRFS	5 -LRFS	10 - LRFS
Treated	97,77%,	97,77%,	97,77%,	NS
versus
Observed	97,14%,	95,57%	91,75%.
Treated
Low risk	100%	100%	100%	NS
versus
Medium risk	96%	96%	96%
Observed
Low risk	93,75%	93,75%	84,38%,	NS
versus
Medium risk	100%	97,06%,	97,06%,

OS: overall survival, DFS: disease-free survival, LRFS: local relapse-free survival.